EGCG suppresses PD-1 expression of T cells via inhibiting NF-κB phosphorylation and nuclear translocation
Zhong-Da Li,Fangfang Liu,Yanqiao Zeng,Yingnan Liu,Wenhe Luo,Feng Yuan,Su Li,Qi Li,Jiaxin Chen,Mayumi Fujita,Guofang Zhang,Yang Li
DOI: https://doi.org/10.1016/j.intimp.2024.112069
IF: 5.714
2024-04-22
International Immunopharmacology
Abstract:Epigallocatechin-3-gallate (EGCG) is an important tea polyphenol with anti-tumor potential. Our previous studies revealed that EGCG was a promising immune checkpoint inhibitor (ICI) as it could downregulate expression of programmed cell death 1 ligand 1 (PD-L1) in tumor cells, thereby resulting tumor killing effect. In particular, EGCG can effectively avoid the inflammatory storm caused by anti-tumor therapy, which is a healthy green capacity absent from many ICIs. However, the relationship between EGCG and programmed cell death 1 (PD-1) of T cells remains unclear. In this work, we explored the effect of EGCG on T cells and found that EGCG suppressed PD-1 via inhibiting NF-κB phosphorylation and nuclear translocation. Furtherly, the capability of EGCG was confirmed in tumor-bearing mice to inhibit PD-1 expression in T cells and enhance apoptosis in tumor cells. These results implied that EGCG could inhibit the expression of PD-1 in T cells, thereby promoting anti-tumor effects of T cells. EGCG will be a promising candidate in anti-tumor therapy.
pharmacology & pharmacy,immunology